Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Young and Innovative: how to help young entrepreneurs be more innovative – a peer learning project (YoungInnovative)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: Coordination and support actions
Countries involved: Hungary,Poland,Slovenia
Call: peer learning of innovation agencies (H2020-INNOSUP-2014-5, 2014)
Start date: 2016-05-01
End date: 2016-11-30
Duration (months): 7.0
Total project cost (EUR): 50000.0
EU funding (EUR): 50000.0
Participants: 4
Project status: CLOSED

The system of business environment institutions plays an important role in the diffusion of technology process and assists the innovative entrepreneurship development. Their support is especially important in case of young entrepreneurs, which very often have innovative ideas but they lack the knowledge and the resources to transform it into solid business. The number and variety of BEI ie. Business centres, innovation centres, financial institutions and their offer, according to the studies in point. 1.1 and data available in the work program, are insufficient for the appropriate innovation stimulation in the partner countries, which at the same time affects the level of innovation and the competitiveness of the European economy. That is why TARR, EPLD, CTRIA and BARR decided to join their forces and by sharing knowledge and experience try to contribute in solving problem mentioned above. The main objective of this project is to develop through the lifetime of the project (7 months) recommendations to improve systems supporting innovation among young entrepreneurs, applied by specialized business environment institutions, using the Twinning Advanced method and then to disseminate them in the partners’ regions and countries and other EU Member States. The T+ methodology involves peer learning of equal partners. Therefore it is possible not only to exchange and disseminate existing solutions but also to develop recommendations for the new ones, which will eventually become good practices in supporting innovation. In order to achieve the main and specific objectives the work‐flow of YoungInnovative will comprise a one phase process, which is the development and dissemination of Design Option Paper.

Keywords: cooperation,peer learning,smes,young,entrepreneur,innovative
Industrial Titanium-Plating Process for the Manufacturing of Light-Weight Composite Parts (TiPlate)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Israel
Call: SME instrument (H2020-EIC-SMEInst-2018-2020-3, 2020)
Start date: 2020-11-01
End date: 2023-07-31
Duration (months): 33.0
Total project cost (EUR): 2654011.25
EU funding (EUR): 1857807.88
Participants: 1
Project status: SIGNED

Polymertal Ltd., founded in Israel in 2007 and with a multi-disciplinary team of 40, offers specialized chemical surface etching technologies that enable superior metal plating of polymers. We have created a proprietary surface etching method that can produce hybrid metal-polymer components of complex geometries, using novel 3D printing techniques and metal post-treatment via a highly cost- and time-efficient industrial manufacturing process. Now, we are tackling the problem of using titanium-based parts. Because of its strength-to-density ratio, corrosion resistance and biocompatibility, titanium is highly useful for lightweight, high-strength applications (e.g. aerospace), for medical implant materials and devices and use in harsh environments (e.g. industrial). However, it cannot be cast like aluminium or iron, and it is more expensive due to its laborious and energy-intensive extraction so final costs of titanium-based parts often outweigh the benefits. To overcome this, Polymertal has developed a novel, titanium plating process called TiPlate, which allows us to manufacture lightweight, high performance, corrosion-resistant, biocompatible titanium-plated polymer components and final parts. Compared to titanium metal parts, TiPlate significantly reduces the titanium required, saving 70+% of costs and 60% of weight, while strengthening the pure polymer parts by 30-50%. We seek EIC Accelerator support for process optimization and upscaling to be able to offer the medical and aerospace industries a cost-effective alternative to the currently available options (costly machined or 3D printed titanium metal parts). We are requesting blended finance (Grant: €1.85M, Equity: €3.5M), in order to push TiPlate to the market by Q3 of 2023, generating EBT of €11M by the 5th year of commercialisation (2026). Considering total project cost of €5.35M as investment and WACC 12.5%, we have an NPV of €2.57M and IRR of 19.8% from 2020 to 2026.

Keywords: titanium,polymers,advanced manufacturing,3d printing,hybrid parts,metal plating,titanium plating,metal replacement,industry 4 0,medical implants,aircraft materials,complex geometries
Stimuli-Responsive Nanoplatform to Combine Magnetic Hyperthermia with Immunemodulators Delivery for Glioblastoma Treatment (MHT-ImmunoEnhancer)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Reintegration panel
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Italy
Call: Individual Fellowships (H2020-MSCA-IF-2018, 2018)
Start date: 2019-10-01
End date: 2021-09-30
Duration (months): 24.0
Total project cost (EUR): 183473.28
EU funding (EUR): 183473.28
Participants: 1
Project status: CLOSED

Glioblastoma (GBM) is one of the most lethal and untreatable human tumours, and is characterized by its extremely poor prognosis. Conventional therapies, including surgery, radiotherapy and chemotherapy, have not resulted in major improvements in the survival, due to high recurrence and tumour spreading. Therefore, there is an urgent need to develop new effective therapies to improve patient survival. The establishment of an immunosuppressive tumour microenvironment (TME) in GBM is known to limit the cytotoxic effects of conventional therapies and in this context, myeloid-derived suppressor cells (MDSCs) play a critical role by promoting immune tolerance, tumour growth and spreading. Hyperthermal therapy in GBM has resulted in improved immune reactivity of tumours, despite this, its effectivity has been limited by its inability to overcome the immunosuppressive TME and induce strong systemic antitumour responses. Consequently, targeting MDSCs in combination with thermal ablation therapies appears to be a very promising strategy. The goal of the MHT-ImmunoEnhancer project is the development of a dual stimuli-responsive hybrid polymer/Iron oxide nanocubes (IONCs) delivery system in order to combine local fever-range Magnetic Hyperthermia (MHT) with MDSC depletion-targeted immunotherapy for intratumoral treatment of GBM. The specific objectives of our strategy are, 1) to exploit the superior heating efficiency of the hybrid polymer/IONCs platforms to induce tumour damage. 2) To turn the immunosuppressive TME into an immunosupportive one, by local delivery of CpG oligonucleotide; along with 5-Fluorouracil (5-FU), a chemotherapeutic agent. 3) To release CpG and 5-FU specifically at the tumour site under the appropriate stimulus (pH or enzymes/temperature), thus enhancing their tumour retention and therapeutic effect. All these actions will result in the reduction of T-cell-suppressive activity of MDSCs, enhancement of antitumour immune response and tumour regression.

Keywords: magnetic hyperthermia,immunotherapy,nanotechnology,glioblastoma,drug delivery
The rise and fall of metastatic clones under immune attack (EVOMET)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: United Kingdom
Call: Individual Fellowships (H2020-MSCA-IF-2018, 2018)
Start date: 2019-05-01
End date: 2021-08-07
Duration (months): 24.0
Total project cost (EUR): 224933.76
EU funding (EUR): 224933.76
Participants: 1
Project status: CLOSED

Colorectal cancer is the second most common cancer in Europe, and although screening has drastically increased survival, a fraction of patients still develops metastatic disease. These patients have a 5-year survival rate of 14% compared to 70% for those non-metastatic (SEER 18). For the majority of cases, the primary tumour is successfully resected, but disease relapse arises due to undetectable metastases. How metastatic clones arise within the primary tumor and adapt to their microenvironment acquiring the capacity of colonize new niches remain unknown. In this project, we aim to use evolutionary analysis combined with state of the art high-throughput technologies to analyse the relationship between the immune system and the progression to metastatic disease. Recently, Zapata and colleagues analysed the relationship between natural selection and the immune system using more than 20 publicly available cancer datasets. The results demonstrated that the presence of neoantigens in the course of tumour development is constrained by the strength of immune activity (immunoediting). In metastasis, malignant clones must escape immune surveillance to colonise new environments. Therefore, we hypothesize that the presence of neoantigens under negative selection in primary tumours will inform us of the cancer cells' ability to disseminate, and ultimately, settle in distant niches. To test our hypothesis, we will develop a patient- specific method to quantify immunoediting across three different cohorts of primary-metastasis matched samples. Ultimately, the extent of immunoediting can be used to explain the underlying causes of metastatic progression allowing, in the future, the development of better treatment strategies.

Keywords: genetic and genomic variation of metastasis,cancer evolution
Accurate assessment of thrombosis risk in systemic lupus erythematosus (ThromboSLE)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Biotechnology
Action type: SME instrument
Countries involved: Netherlands
Call: Dedicated support to biotechnology SMEs closing the gap from lab to market (H2020-SMEINST-1-2016-2017, 2017)
Start date: 2018-03-01
End date: 2018-08-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Patients with systemic lupus erythematosus (SLE) are at high risk for thrombosis, a major and life-threatening complication of SLE and one of the main causes of death in SLE. There is a need for the accurate identification of patients that are at highest risk, as in this group the risk/benefit ratio for anticoagulant prophylaxis is advantageous. As in SLE thrombosis is caused by disease-specific mechanism, current testing methods fail to accurately assess thrombosis risk in SLE. Applying its unique expertise in functional analysis of blood plasma and cellular components, the Dutch SME Good Biomarker Sciences (GBS) has developed ThromboSLE, an innovative test to assess thrombosis risk in SLE with high sensitivity and specificity. Apart from reducing morbidity and mortality from thrombosis-related complications, the introduction of ThromboSLE will reduce healthcare costs: Thrombotic events cause high healthcare costs, including direct cost for interventions and rehabilitation cost and the total median costs for prophylaxis are four times lower than those for thrombotic event management. This opens a strong business opportunity for GBS, which aims to offer the test to hospitals treating and monitoring SLE patients in Europe and worldwide. The commercial exploitation of the diagnostic product will have substantial impact on GBS with respect to company growth and business strategy. With 160,000 SLE patients in the target market Western Europe, GBS forecasts to generate cumulated profits of €6.6 million from ThromboSLE sales by 2025. Before entering and investing into the innovation project (SMEi phase II) and to reach market readiness for ThromboSLE, GBS aims to conduct a feasibility study (SMEi phase I) for final verification of the technological as well as economic viability of the product.

Keywords: systemic lupus erythematosus sle,thrombosis risk,diagnostic service,in vitro diagnostic
Surface-COnfined fast-modulated Plasma for process and Energy intensification in small molecules conversion (SCOPE)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Synergy grants
Action type: ERC actions
Countries involved: Italy,Australia,Belgium,Netherlands,United Kingdom
Call: ERC Synergy Grant (ERC-2018-SyG, 2018)
Start date: 2019-04-01
End date: 2026-03-31
Duration (months): 84.0
Total project cost (EUR): 10400695.38
EU funding (EUR): 9979269.379999999
Participants: 5
Project status: SIGNED

The SCOPE project will introduce a ground-breaking approach to use renewable energy in three major industrial reactions: 1) N2 fixation, 2) CH4 valorization and 3) CO2 conversion to liquid solar fuels. We will use non-thermal plasma, which has large potential to convert these small (low reactive) molecules under near ambient temperature and pressure, particularly for distributed processes based on renewable energy. The new processes have drastically lower carbon footprint (up to over 90% with respect to current ones). Furthermore, CO2 conversion is crucial for a world-based distribution of renewable energy. However, the selectivity and energy efficiency of plasma technologies for these reactions are too low, making radically new approaches necessary. The Project idea is to realize a highly innovative approach for non-thermal plasma symbiosis with catalysis. By inducing excited states in solid catalysts to work in synergy with the excited short-lived plasma species, we introduce a brand new idea for catalyst-plasma symbiosis. In addition, we introduce a fully new concept of nano-/micro-plasma array through a novel electrode design, to generate the plasma at the catalyst surface, thereby overcoming long distance transport. By embedding ferro-magnetic nano-domains in the catalyst support and inducing radiofrequency heating, we create fast temperature modulations directly at the catalyst active sites. Combining these elements, the project will overcome the actual limits and enhance the selectivity and energy efficiency to levels suitable for exploitation. This requires a synergy over different scale elements: nano at catalyst, micro at the level of modelling plasma generated species, milli at the reactor scale and mega at the plant level for sustainability-driven opportunity guidance and impact assessment by Life-Cycle-Assessment. The synergy value derives from the integration of the PI competencies over this entire dimensional-scale level.

Keywords: non thermal plasma,process and energy intensification,surface confined plasma,ammonia
Collective Intelligence for Energy Flexibility (COLLECTiEF)

Framework: Horizon 2020 — Societal Challenges
Programme: Secure, clean and efficient energy
Theme: Reducing energy consumption and carbon foorpint by smart and sustainable use
Action type: Innovation actions
Countries involved: Italy,Italy,Italy,Italy,Cyprus,Sweden,Norway,Sweden,Norway,Hungary,Sweden,Norway,France
Call: Upgrading smartness of existing buildings through innovations for legacy equipment (H2020-LC-SC3-EE-2020-2, 2020)
Start date: 2021-06-01
End date: 2025-05-31
Duration (months): 48.0
Total project cost (EUR): 4588167.5
EU funding (EUR): 3987794.75
Participants: 14
Project status: SIGNED

The COLLECTiEF consortium will enhance, implement, test and evaluate an interoperable and scaleable energy management system based on Collective intelligence (CI) that allows easy and seamless integration of legacy equipment into a collaborative network within and between existing buildings and urban energy systems with reduced installation cost, data transfer and computational power while increasing data security, energy flexibility and climate resilience. This is done through developing software and hardware packages to install and smart up buildings and their legacy equipment on large scale, meanwhile to maintain simple and robust communication with the energy grid. The proposal includes the following objectives: (1)Enhancement and adaptation of algorithms for creating a CI-based energy flexible network (2)Realization of CI-based cost-effective system components with easy deployment and maintenance (3)Demonstration and testing of a CI-based energy network in the real environment (4)Testing and implementing a scalable and customizable occupant-centric fusion sensor network for accurate and non-invasive environmental monitoring (5)Designing and implementing a smart, user-centric and user friendly digital platform for interacting with users and controlling technical building systems (6)New business model for energy services including a clear model for commercialization of COLLECTiEF system. This will be achieved by building on technologies developed in previous EU-funded projects and by expertise from the scientific and commercial partners of this proposal, involving a number of highly innovative SMEs. The consortium forms a full value chain with academic partners, component manufacturers, building owners and - associated through LoIs - energy providers. The provided scalable solutions will integrate seamlessly with existing legacy equipment, and will facilitate demand-side management of multiple buildings, enhancing energy flexibility and resilience in urban areas.

Keywords: collective intelligence,climate resilience
A Genetic View of Influenza Infection (GV-FLU)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Integrative Biology: from Genes and Genomes to Systems
Panel description: Genetics, epigenetics, genomics and other ‘omics studies, bioinformatics, systems biology, genetic diseases, gene editing, innovative methods and modelling, ‘omics for personalised medicine
Countries involved: Israel
Call: ERC Starting Grant (ERC-2014-STG, 2014)
Start date: 2015-07-01
End date: 2021-06-30
Duration (months): 72.0
Total project cost (EUR): 1497000.0
EU funding (EUR): 1497000.0
Participants: 1
Project status: CLOSED

Inherited variation in the quantity and functionality of immune cells plays a key role in determining phenotypic diversity between individuals. Surprisingly little is known, however, about the specific contribution of immune cell subsets to variation in phenotypes such as susceptibility to infectious diseases and the underlying genetic variation. In many complex diseases, we currently have a poor understanding of the driver cell types that are responsible for inherited variation in disease states. A comprehensive mapping of quantities and functions of immune cell types during the course of disease, in large cohorts, bears the potential to transform genetic research; provides understanding of the genetic and immune basis of phenotypes; and reveals the key driver cell subsets. Here I aim to derive a mechanistic understanding of how variation in quantity and function of immune cell subsets mediates inherited variation in disease states. I propose to develop a computational model that integrates predicted quantities and functions of cell subsets with genotypic and phenotypic information, leading to specific hypotheses on physiological regulation and the particular cell subsets that drive phenotypic diversity. To circumvent the technical difficulty in quantifying a large number of immune cell types, I will profile gene expression and computationally quantify changes in a large number of cell types. I will develop and apply this strategy to dissect Influenza infection in mice. Since changes in immune responses play a key role in complex diseases, our ability to predict variation in immune responses from genotypes would have important clinical implications. This project has far reaching implications as the paradigm developed here will transform quantitative genetics studies as well as systems immunology research of complex disease. This approach will be applicable to any mammalian disease, allowing researchers to dissect their own systems at unprecedented detail.

Keywords: complex traits,quantitative genetics,immune response,network reconstruction,computational,biology,influenza infection
‘Key account management’ for the EIC Pilot beneficiaries and ‘Enhancing SME innovation management capacity’ as proinnovative services for SMEs in the regions of Southern Poland (KAM2SouthPL2)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: Specific Grant agreement
Countries involved: Poland,Poland,Poland,Poland,Poland
Call: H2020 ENTREPRISE EUROPE NETWORK SGA4 2020-2021 (H2020-EEN-SGA4-2020-2021, 2019)
Start date: 2020-01-01
End date: 2021-12-31
Duration (months): 24.0
Total project cost (EUR): 175630.0
EU funding (EUR): 175630.0
Participants: 9
Project status: CLOSED

The general objective of the project is to contribute to smart growth of Southern regions of Poland by increasing the efficiency and effectiveness of investments in innovation and by contributing to more efficient connection of links along the innovation chain and by this – to contribute to the smart EU growth. The specific objectives of the project are: (1) efficient management of the relation between SME (beneficiary of the European Innovation Council (EIC) Pilot under H2020) and the coach in purpose to increase the number of projects financed within Horizon 2020 programme completed with a successful commercialization and (2) development of regional SME innovation management capacity: by carrying out innovation management gap analysis, development of the tailored action plan for increasing the effectiveness and efficiency of their innovation management system and implementation of the targeted actions to address bottlenecks and weak points between the innovation capabilities and innovation goals. The objectives will be achieved by performing two kinds of service packs: Key Account Manager and Enhancing SME innovation management capacity, based on the common for the whole Enterprise Europe Network standard, compliant with European Innovation Management standards - CEN/TS 16555:1. The project is relevant to the Work Programme in Horizon 2020 and helps to overcome lack of capacity in innovation management, recognised as an important barrier in creating economic impact on innovation activities in SMEs. The project is addressed to the specific challenge and scope of the topic and offers mentoring and coaching services to beneficiaries who need this help. The project will make SMEs high quality innovation support services available where these are absent or unaffordable on local markets. The project aims at support projects with an European dimension that lead to radical changes in how business is done.

Keywords: innovation,development,sme instrument,fast track to innovatio,fet open,horizon 2020,enhancing sme innovation management capacity,innovation strategy,innovation chain,smart,growth